Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Keoxifene (LY156758) is a new benzothiophene-derived antiestrogen with an extremely low degree of estrogenicity. Administration of 1-20 mg/kg per day inhibited the growth of 7, 12-dimethylbenzanthracene (DMBA)-induced mammary tumors in rats. The degree of inhibition of mammary tumor growth was similar to that observed with tamoxifen treatment.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002369:Castration; D004353:Drug Evaluation, Preclinical; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008325:Mammary Neoplasms, Experimental / Q000503:physiopathology*; D010880:Piperidines / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D020849:Raloxifene Hydrochloride; D051381:Rats; D011919:Rats, Inbred Strains; D013629:Tamoxifen / Q000627:therapeutic use
D004965:Estrogen Antagonists; D010880:Piperidines; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene; D011388:Prolactin; D007986:Luteinizing Hormone